Document is current
Any future updates will be listed below
-
Authors
Hoppe, Michal M https://orcid.org/0000-0002-0364-6080
Jaynes, Patrick
Wardyn, Joanna D
Upadhyayula, Sai Srinivas
Tan, Tuan Zea https://orcid.org/0000-0001-6624-1593
Lie, Stefanus
Lim, Diana G Z
Pang, Brendan N K
Lim, Sherlly
P S Yeong, Joe
Karnezis, Anthony
Chiu, Derek S
Leung, Samuel
Huntsman, David G
Sedukhina, Anna S
Sato, Ko
Topp, Monique D
Scott, Clare L
Choi, Hyungwon https://orcid.org/0000-0002-6687-3088
Patel, Naina R
Brown, Robert https://orcid.org/0000-0001-7960-5755
Kaye, Stan B
Pitt, Jason J
Tan, David S P https://orcid.org/0000-0001-9087-5262
Jeyasekharan, Anand D https://orcid.org/0000-0001-9816-6137
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/TA/0052/2016)
MOH | National Medical Research Council (NMRC/CSA‐INV/0016/2017)
MOH | National Medical Research Council (NMRC/CIRG/1400/2014)
CRUK Imperial Centre
Imperial Experimental Medicine Centre
Cancer Research UK and Ovarian Cancer Action
Cancer Science Institute of Singapore PhD Graduate Scholarship
National Research Foundation Singapore
Ministry of Education Singapore
- License Information
-
More Information
Article History
Received: 2 September 2020
Revised: 4 February 2021
Accepted: 9 February 2021
First Online: 11 March 2021
Conflict of interest
: ADJ; received consultancy fees from Turbine Ltd, AstraZeneca, Janssen and MSD, along with travel funding from Perkin Elmer, and research funding from Janssen. DSPT; honoraria from AstraZeneca, Roche, Bayer, MSD, Merck Serono, Tessa Therapeutics, Novartis, and Genmab and research funding from AstraZeneca, Bayer and Karyopharm. The other co‐authors declare that they have no conflict of interest.
